Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 辽宁成大生物股份有限公司成立于2002年6月，公司秉承“面对生命，只有责任”的理念，致力于研发、生产和推广“国际水平、国内领先”的生物制品，主营产品为人用狂犬病疫苗和人用乙脑灭活疫苗。 公司位于辽宁沈阳浑南国家高新技术产业开发区内的生产基地占地近百亩，建筑面积5万多平方米，员工1000余人。建有人用狂犬病疫苗、乙脑疫苗原液车间及疫苗灌装车间。已投产车间都已通过国家新版GMP认证，另在本溪建设厂区，作为部分新品种生产基地。 成大生物公司生产人用狂犬病疫苗在国内市场占有率始终保持领先，并占据国际市场的优势地位，产品销售至三十多个国家及地区。 公司专注于疫苗行业，始终秉承“正直诚信、仁爱和谐”的核心价值观，坚持“面对生命，只有责任”的理念，致力于研发、生产、推广国内领先、国际水平的生物制品。未来公司将继续坚持以创新为驱动，以产品为主导，以专业化为保障、效率致胜的创新可持续发展战略，把人民健康放在首位，严控产品质量，继续完善社会责任管理，聚焦人用疫苗领域，建设智能化车间，提高生产效率，并不断研制创新产品，力争为中国生物制品行业发展贡献力量，践行国家创新及高质量发展战略。
Main Business 人用疫苗的研发、生产和推广销售。
Legal Representative 李宁
Top Executives
董事长：李宁
董事：杨俊伟,毛昱,崔建伟,董丙建,李宁,张善伟
独立董事：陈克兢,张克坚,刘晓辉
Top 5 Shareholder
Shareholder name Nature Holding Date
辽宁成大股份有限公司限售股54.67%30/09/2024
杨旭流通A股1.59%30/09/2024
庄久荣流通A股1.08%30/09/2024
香港中央结算有限公司流通A股0.70%30/09/2024
刘蕴华流通A股0.60%30/09/2024
Company Secretary 崔建伟
Solicitors 辽宁恒信律师事务所
Auditors 容诚会计师事务所（特殊普通合伙）
Tel No 024-83782632
Fax No 024-23789772
Website www.cdbio.cn
Email lncdsw@cdbio.cn
Company Address
Register: 辽宁省沈阳市浑南新区新放街1号
Office: 辽宁省沈阳市浑南新区新放街1号
Listing Date 28/10/2021
Shares Capital
Shares Capital: 416,450,000
Total A Share: 416,450,000
Listed A Share: 188,786,236
Non-tradable A Share: 227,663,764
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 1.120
DPS(RMB)* ¥ 0.800
NBV Per Share(RMB)* ¥ 23.050
Market Capitalization(RMB) 5.043B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.